BioPharmArena.com

The newest version of GE’s featured MUSE data management system incorporates upgrades in information technology, ECG management processes and clinical report editing in an all-digital environment for truly paperless workflow. “The MUSE version 7. 1 offers new benefits including additional options that enhance clinical workflows and improved IT connectivity,” said Dr. Matthias Weber, cardiologist and vice president of GE Healthcare’s Diagnostic Cardiology business. “The system is intended to better meet the needs for accessing comprehensive ECG data across the enterprise.”

Clinical Benefits

MUSE v7.1 provides high-fidelity digital access to resting ECG, Stress and Holter tests, allowing the clinician to review and edit studies on-line, from the comfort of home, anytime night or day. Clinical workflow is enhanced through the use of new display formats, magnification and measurement tools and statement editing capabilities. GE has added further measurement options, meeting the needs of pediatric cardiologists and those in other specialty areas. GE’s innovative Marquette® Serial Comparison program makes algorithmic comparative analysis available, on-demand. In addition, a number of IT capabilities are available to provide clinicians access to important patient data both inside and outside of the workplace.

Information Technology Benefits

Information Technology (IT) highlights include both a SQL 2005 relational database and a Windows Server 2003 operating system and is available as a software-only offering. THE MUSE system offers extensive HL7 interfaces and web integration with most major vendor EMR systems. A dedicated team is available to assist you during your implementation and integration needs. Additionally, the MUSE system provides an end-to-end workflow solution through optional wireless or LAN networking to the MAC5500 and 3500 electrocardiographs. Utilizing the hospital infrastructure for connectivity, along with the MUSE HL7 interface, the user can download patient demographic information and orders directly to the electrocardiograph.

Pharmaceutical Clinical Trials

The MUSE system has long been an important tool in addressing the unique challenges of pharmaceutical clinical trials. The recent MUSE v7 improvements include an Interval Editor option, with capabilities for ICH E-14 “thorough QT study” criteria. It also includes 21CFR Part 11 compliance aids and extensive XML export capabilities to assist in creating a compliant, readily auditable environment for submitting results to the FDA without a cumbersome certification process.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at http://www.gehealthcare.com.